Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Web – sheet or filament bases; compositions of bandages; or...
Reexamination Certificate
2000-11-15
2004-06-29
Spear, James M. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Web, sheet or filament bases; compositions of bandages; or...
C424S422000, C424S434000, C424S435000, C424S448000, C424S449000, C424S430000, C424S447000
Reexamination Certificate
active
06756051
ABSTRACT:
The present invention relates to bioadhesive, closed-cell foam film, sustained release, delivery devices for administering an active agent or combination of active agents to a subject. The present invention also relates to methods for making such delivery devices and to methods for using such bioadhesive delivery devices to provide a sustained, controlled release of an active agent or combination of active agents to a subject, preferably a near zero-order release of the active agent or combination of active agents.
Prescription and over-the-counter medications and other pharmaceutical products have traditionally been administered through oral ingestion, nasal sprays, injections and suppositories. For example, many pharmaceutical dosage forms are administrated orally in the form of solid shaped articles such as tablets, pills, caplets and capsules that retain their shape under moderate pressure. Generally these dosage forms are designed to be swallowed whole or chewed to deliver the medication with adequate amounts of liquid. Some patients, particularly pediatric and geriatric patients, have difficulty swallowing or chewing such solid dosage forms. Certain patients such as children or animals often resist taking medications, and may try to hide such dosage forms in order to spit it out later. In addition, many pediatric and geriatric patients are unwilling to take such solid dosage forms because they have difficulty swallowing them even when liquids are consumed therewith. Furthermore, the availability of liquids at the time of administering medications may be limited for certain patients and may be restricted for certain diseases and/or treatments.
Chewable tablets provide some advantages over conventional tablets. Such chewable tablets, however, are not suitable for children wearing braces and the taste of certain active agents may be unpleasant and difficult to mask in a chewable tablet. In addition, the use of chewable tablets may not eliminate the desire or need to administer water or some other liquid therewith.
Furthermore, the standard oral dosage forms, such as tablets, pills, caplets, and capsules, are designed for short residence time in the mouth. Absorption of the active agent from these dosage forms typically occurs in the gastrointestinal (GI) tract, after the active agent has separated from the dosage form and dissolved in the gastric fluids. For some active agents, it is desirable to achieve absorption through a mucosal tissue in order to accelerate onset of the therapeutic effect.
Many active agents are poorly absorbed, even after they are dispersed in the stomach, because of low solubility or slow dissolution rate in the gastric fluids. Tablets may be formulated so as to be quick dissolving. These tablets are commonly placed on the tongue and disintegrate rapidly in the oral cavity. These dosage forms, however, are not fixed to a mucosal tissue and may move around in the mouth. Consequently, these dosage forms do not overcome the risk associated with choking or gagging that occurs with subjects having limited control of their swallowing reflexes.
Accordingly, what is needed are bioadhesive delivery devices which provide for the sustained, controlled release of an active agent or combination of active agents to a subject, which delivery devices are easy to use and are comfortable while in place in a subject.
Glossary
The following definitions are provided to facilitate an understanding of certain terms used frequently herein.
The term “bioadhesive delivery device” as used herein and in the appended claims means any solid substance, of any shape, which is intended to be adhered to a mucosal tissue of a subject. The term “buccal device” or “buccal delivery device” means a bioadhesive device which is intended to be inserted into the buccal cavity. The term “vaginal device” or “vaginal delivery device” means a bioadhesive device which is intended to be inserted into the vagina.
The term “bioadhesive, closed-cell foam film, sustained release, delivery device” as used herein and in the appended claims means a bioadhesive delivery device comprising a closed-cell foam film substance designed to provide a sustained, controlled release an active agent or combination of active agents to a subject. These bioadhesive delivery devices preferably include buccal delivery devices and vaginal delivery devices.
The term “controlled release” as used herein and in the appended claims means that a predetermined dosage of an active agent or combination of active agents is administered to a subject over a period of time.
The term “bioadhesive force” as used herein and in the appended claims is a quantitative value for tackiness (grams) which simulates the adhesion of the bioadhesive, closed-cell foam film, sustained release, delivery devices of the present invention upon contact with a moist mucosal tissue. The bioadhesive force preferably should be at least 10 grams, more preferably at least 15 grams, most preferably at least 20 grams.
The term “% elongation” as used herein and in the appended claims is measured when a bioadhesive, closed-cell foam film, sustained release, delivery device of the present invention snaps as sufficient force is applied to exceed the elastic limit thereof.
The term “modulus” as used herein and in the appended claims is a measurement of the stiffness of a bioadhesive, closed-cell foam film, sustained release, delivery device of the present invention.
The term “mucosal tissue” as used herein and in the appended claims means any moist mucosal surface of the subjects body as deemed appropriate for the systemic or local delivery of an active agent or combination of active agents including oral, nasal, vaginal, rectal and ocular tissues. The term “oral tissue(s)” as used herein and in the appended claims includes lingual, sub-lingual, buccal, gingival and palatal surfaces; most preferably lingual, sub-lingual and buccal surfaces.
The term “permeation enhancer” as used herein and in the appended claims means a natural or synthetic molecule which facilitates the absorption of a given active agent or combination of active agents through a mucosal tissue.
The term “release period” as used herein and in the appended claims means the period of time subsequent to administration of a bioadhesive, closed-cell foam film, sustained release, delivery devices of the present invention during which the delivery device releases an active agent or combination of active agents to a subject.
The term “subject” as used herein and in the appended claims means an animal, preferably a mammal, most preferably a human.
The term “sustained release” as used herein and in the appended claims means the continual release of an active agent or combination of active agents over a period of time.
The term “tensile strength” as used herein and in the appended claims is expressed in pounds per square inch (psi) and is the property of a bioadhesive, closed-cell foam film, sustained release, delivery device of the present invention that requires a load to cause load deformation failure of said film.
The term “thickness” as used herein and in the appended claims by measurements in mil (a mil=one thousandth of an inch) is determined when a bioadhesive, closed-cell foam film, sustained release, delivery device of the present invention is placed between two microscopic slides.
The term “water content” as used herein and in the appended claims is the % residual water content per unit dose as measured to the Karl Fisher method and expressed as percent of the dry weight of a bioadhesive, closed-cell foam film, sustained release, delivery device of the present invention.
The term “zero order release” in relation to release kinetics as used herein and in the appended claims means that the rate of release of the active agent or active agents from a delivery device is a linear function with time.
SUMMARY OF THE INVENTION
In a preferred embodiment of the present invention, bioadhesive, closed-cell foam film, sustained release, delivery devices are provided which contain: (a) an active agent or combi
Chen Li-Lan H.
Liang Alfred
Tao Li
Zheng Xu
Dechert LLP
Howard Sharon
Ryan John W.
Spear James M.
LandOfFree
Bioadhesive, closed-cell foam film, sustained release,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bioadhesive, closed-cell foam film, sustained release,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bioadhesive, closed-cell foam film, sustained release,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3330958